SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Mark Novara as Executive Vice ...
SAN DIEGO, November 06, 2025--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September ...
Investor's Business Daily on MSN
Tandem Diabetes Care Hits 80-Plus Relative Strength Rating Benchmark
When building your watch list, look for stocks with an 80 or higher RS Rating. Tandem Diabetes Care TNDM is one stock that ...
Rosen Law Firm’s probe into Tandem Diabetes Care (TNDM) after a voluntary correction of certain t:slim X2 insulin pumps, and the roughly 20% share drop that followed, has investors reassessing risk ...
GAAP margins including GAAP gross margin and GAAP operating margin are calculated using GAAP sales. Non-GAAP margins including non-GAAP gross margin, non-GAAP operating margin, and adjusted EBITDA ...
15 analysts have shared their evaluations of Tandem Diabetes Care (NASDAQ:TNDM) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a ...
Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by The New England Journal of Medicine ...
Tandem Diabetes delivered weaker-than-expected Q4 results but followed with strong forward guidance. The company launched four new products in the U.S. last quarter. Tandem Diabetes climbed as ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
Tandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels This sub-analysis is the first study to evaluate ...
“The strength of our first quarter performance was driven by more than 20% worldwide sales growth, including our highest quarter ever outside the United States,” said John Sheridan, president and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results